Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

BET inhibitor

DRUG CLASS:

BET inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

MYC expression	Diffuse Large B Cell Lymphoma	MYC expression	Diffuse Large B Cell Lymphoma	RG6146 Sensitive: C2 – Inclusion Criteria RG6146 Sensitive : C2	RG6146 Sensitive: C2 – Inclusion Criteria RG6146 Sensitive : C2
MAF overexpression	Multiple Myeloma	MAF overexpression	Multiple Myeloma	JQ-1 + 10058-F4 Resistant: C3 – Early Trials JQ-1 + 10058-F4 Resistant : C3	JQ-1 + 10058-F4 Resistant: C3 – Early Trials JQ-1 + 10058-F4 Resistant : C3
EPCAM expression	Triple Negative Breast Cancer	EPCAM expression	Triple Negative Breast Cancer	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3
SOX9 expression	Triple Negative Breast Cancer	SOX9 expression	Triple Negative Breast Cancer	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3
SF3B1 mutation	Acute Myelogenous Leukemia	SF3B1 mutation	Acute Myelogenous Leukemia	venetoclax + ABBV 075 Sensitive: C3 – Early Trials venetoclax + ABBV 075 Sensitive : C3	venetoclax + ABBV 075 Sensitive: C3 – Early Trials venetoclax + ABBV 075 Sensitive : C3
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	venetoclax + ABBV 075 Sensitive: C3 – Early Trials venetoclax + ABBV 075 Sensitive : C3	venetoclax + ABBV 075 Sensitive: C3 – Early Trials venetoclax + ABBV 075 Sensitive : C3
GJA1 expression	Triple Negative Breast Cancer	GJA1 expression	Triple Negative Breast Cancer	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3
CD24 expression	Triple Negative Breast Cancer	CD24 expression	Triple Negative Breast Cancer	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3
U2AF1 mutation	Acute Myelogenous Leukemia	U2AF1 mutation	Acute Myelogenous Leukemia	venetoclax + ABBV 075 Sensitive: C3 – Early Trials venetoclax + ABBV 075 Sensitive : C3	venetoclax + ABBV 075 Sensitive: C3 – Early Trials venetoclax + ABBV 075 Sensitive : C3
MYC expression + MYC rearrangement	Lymphoma	MYC expression + MYC rearrangement	Lymphoma	BET inhibitor Sensitive: C3 – Early Trials BET inhibitor Sensitive : C3	BET inhibitor Sensitive: C3 – Early Trials BET inhibitor Sensitive : C3
BRCA wild-type	Triple Negative Breast Cancer	BRCA wild-type	Triple Negative Breast Cancer	talazoparib + ZEN-3694 Sensitive: C3 – Early Trials talazoparib + ZEN-3694 Sensitive : C3	talazoparib + ZEN-3694 Sensitive: C3 – Early Trials talazoparib + ZEN-3694 Sensitive : C3
PRDX1 overexpression	Hepatocellular Cancer	PRDX1 overexpression	Hepatocellular Cancer	GSK525762 Sensitive: C3 – Early Trials GSK525762 Sensitive : C3	GSK525762 Sensitive: C3 – Early Trials GSK525762 Sensitive : C3